BPC-157
Synthetic 15-amino-acid peptide derived from a gastric-protein sequence; most published work remains preclinical.
Mechanism & research rationale
Preclinical literature describes effects involving nitric-oxide signalling, VEGF/VEGFR2-linked angiogenic pathways, fibroblast migration, growth-factor signalling and inflammatory mediators. These are mechanistic hypotheses from laboratory and animal work, not established clinical effects in humans.
Human evidence
A 2025 systematic review of musculoskeletal literature found 35 preclinical studies and only one small clinical study. The human report was uncontrolled and involved 12 people with chronic knee pain, so it cannot establish efficacy or safety. A 2026 development review similarly concludes that clinical development remains rudimentary and that standardized pharmacokinetics, formulations and controlled trials are missing.
Preclinical / translational evidence
Animal studies span tendon, ligament, muscle, bone, gastrointestinal and vascular models. Reported improvements in structural or functional outcomes are hypothesis-generating, but translation from rodent injury models to human disease is uncertain.
Key limitations
- No completed Phase II programme or large randomized controlled trials were identified.
- Human safety data are sparse; manufacturing quality and peptide-related impurities are separate risks from the molecule itself.
- Findings from animal models should not be presented as proven human healing or recovery benefits.